Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation

Journal of Pharmaceutical and Biomedical Analysis

Volumn 76, Issue , 2013, Pages 49-58

  Delbroek, Lore ^a   Van Kolen, Kristof ^a   Steegmans, Liesbeth ^a   da Cunha, Raquel ^b,c   Mandemakers, Wim ^b,c   Daneels, Guy ^a   De Bock, Pieter Jan ^b,d   Zhang, Jinwei ^e   Gevaert, Kris ^b,d   De Strooper, Bart ^b,c   Alessi, Dario R ^e   Verstreken, Patrik ^b,c   Moechars, Diederik W ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

ELISA; LRRK2; Parkinson's disease; S935 phosphorylation

Indexed keywords

ENZYME ANTIBODY; GREEN FLUORESCENT PROTEIN; LEUCINE RICH REPEAT KINASE 2; PS935 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LYSATE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MALE; MASS SPECTROMETRY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TRANSGENE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, LONG-EVANS; SENSITIVITY AND SPECIFICITY;

EID: 84872255908     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.12.002     Document Type: Article

References (29)

1. Martin I., Dawson V.L., Dawson T.M. Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet. 2011, 12:301-325.
2. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
3. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
4. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009, 1:13-24.
5. Tan E.K., Peng R., Teo Y.Y., Tan L.C., Angeles D., Ho P., Chen M.L., Lin C.H., Mao X.Y., Chang X.L. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum. Mutat. 2010, 31:561-568.
6. Kamikawaji S., Ito G., Iwatsubo T. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009, 48:10963-10975.
7. Imai Y., Gehrke S., Wang H.Q., Takahashi R., Hasegawa K., Oota E., Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
8. Ohta E., Kawakami F., Kubo M., Obata F. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett. 2011, 585:2165-2170.
9. Parisiadou L., Xie C., Cho H.J., Lin X., Gu X.L., Long C.X., Lobbestael E., Baekelandt V., Taymans J.M., Sun L. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 2009, 29:13971-13980.
10. Nichols R.J., Dzamko N., Morrice N.A., Campbell D.G., Deak M., Ordureau A., Macartney T., Tong Y., Shen J., Prescott A.R. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 2010, 430:393-404.
11. Dzamko N., Deak M., Hentati F., Reith A.D., Prescott A.R., Alessi D.R., Nichols R.J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localisation. Biochem. J. 2010, 430:405-413.
12. Choi H.G., Zhang J., Deng X., Hatcher J.M., Patricelli M.P., Zhao Z., Alessi D.R., Gray N.S. Brain penetrant LRRK2 inhibitor. ACS Med. Chem. Lett. 2012, 3:658-662.
13. Deng X., Dzamko N., Prescott A., Davies P., Liu Q., Yang Q., Lee J.D., Patricelli M.P., Nomanbhoy T.K., Alessi D.R. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 2011, 7:203-205.
14. Nichols R., Dzamko N., Hutti J., Cantley L., Deak M., Moran J., Bamborough P., Reith A., Alessi D. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J. 2009, 424:47-60.
15. Herzig M.C., Kolly C., Persohn E., Theil D., Schweizer T., Hafner T., Stemmelen C., Troxler T.J., Schmid P., Danner S. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 2011, 20:4209-4223.
16. Biskup S., Moore D., Rea A., Lorenz-Deperieux B., Coombes C., Dawson V., Dawson T., West A. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci. 2007, 8:102.
17. Li X., Tan Y.C., Poulose S., Olanow C.W., Huang X.Y., Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 2007, 103:238-247.
18. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
19. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:16842-16847.
20. Lee B.D., Shin J.H., VanKampen J., Petrucelli L., West A.B., Ko H.S., Lee Y.I., Maguire-Zeiss K.A., Bowers W.J., Federoff H.J. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 2010, 16:998-1000.
21. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
22. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
23. Hermanson S.B., Carlson C.B., Riddle S.M., Zhao J., Vogel K.W., Nichols R.J., Bi K. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation. PLoS ONE 2012, 7:e43580.
24. Dzamko N., Inesta-Vaquera F., Zhang J., Xie C., Cai H., Arthur S., Tan L., Choi H., Gray N., Cohen P. The IkappaB kinase family phosphorylates the Parkinsonâ€TMs disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS ONE 2012, 7:e39132.
25. Li X., Wang Q.J., Pan N., Lee S., Zhao Y., Chait B.T., Yue Z. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS ONE 2011, 6:e17153.
26. Doggett E.A., Zhao J., Mork C.N., Hu D., Nichols R.J. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. J. Neurochem. 2012, 120:37-45.
27. Daniëls V., Vancraenenbroeck R., Law B.M.H., Greggio E., Lobbestael E., Gao F., De Maeyer M., Cookson M.R., Harvey K., Baekelandt V. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem. 2011, 116:304-315.
28. Guo L., Gandhi P.N., Wang W., Petersen R.B., Wilson-Delfosse A.L., Chen S.G. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 2007, 313:3658-3670.
29. Matta S., Van Kolen K., da Cunha R., van den Bogaart G., Mandemakers W., Miskiewicz K., De Bock P.-J., Morais V., Vilain S., Haddad D., Delbroek L., Swerts J., Chávez-Gutiérrez L., Esposito G., Daneels G., Karran E., Holt M., Gevaert K., Moechars D., De Strooper B., Verstreken P. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012, 75:1008-1021.